Citius Oncology, Inc.
Citius Oncology, Inc. (CTOR) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CTOR · as of Jun 9, 2026
Key Statistics
Explore Citius Oncology, Inc. Data
ctor stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 2 · Buy rate: 100.0%
The CTOR analyst consensus is Buy, based on ratings from 2 Wall Street analysts over the past 3 months. The average 12-month price target is $6.00, representing +650.09% upside from the current price of $0.80.
Competitors & Peers
ctor competitorsCTOR
ACTU
APLT
FATE
FBRX
LNSRStock Performance
Full HistoryAbout Citius Oncology, Inc.
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigationa…
what is citius oncology, inc. · ctor stock overview · citius oncology, inc. company profile · who is citius oncology, inc. ceo · ctor NASDAQ · citius oncology, inc. headquarters · citius oncology, inc. business segments
About Stock Overview & Key Data
Citius Oncology, Inc. (CTOR) is a Healthcare company in the Drug Manufacturers - General industry, listed on NASDAQ since Dec 8, 2022. As of the latest trading session, CTOR stock price is $0.80, with a market capitalization of $74.4M. The stock has returned -34.97% over the past 12 months and -20.01% year-to-date.
According to 2 Wall Street analysts, the consensus rating for Citius Oncology, Inc. stock is Buy, with an average 12-month price target of $6.00. In fiscal year 2025, Citius Oncology, Inc. reported revenue of — and net income of -$24.8M. For detailed data — including Citius Oncology, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Citius Oncology, Inc. (CTOR) stock price is $0.80. The stock is traded on NASDAQ under the ticker symbol CTOR. The 52-week range is $0.49 – $6.19.